Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.71 |
| ▸ | FAAH | O00519 | 4/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.51 |
| ▸ | TERT | O14746 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119423 | 1.00 | DNM1 (0.71) | DNM1FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL10937974 | 1.00 | DNM1 (0.71) | DNM1FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL17453344 | 1.00 | DNM1 (0.71) | DNM1FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL220549 | 1.00 | DNM1 (0.71) | DNM1FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL21240011 | 1.00 | DNM1 (0.71) | DNM1FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL8345479 | 1.00 | DNM1 (0.71) | DNM1FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL221500 | 1.00 | DNM1 (0.71) | DNM1FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL165446 | 1.00 | DNM1 (0.71) | DNM1FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL21345153 | 1.00 | DNM1 (0.71) | DNM1FAAHTRPV1ALDH1A1TSHR | |
| SCHEMBL8004895 | 1.00 | DNM1 (0.71) | DNM1FAAHTRPV1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566874-B1 | SOLVENT-FREE ORGANOSILANE QUATERNARY AMMONIUM COMPOSITIONS, METHOD OF MAKING AND USE | RESOURCE DEV LLC (US) | 2023-01-18 | — | — | EP | claimed |
| US-8735618-B2 | Solvent-free organosilane quaternary ammonium compositions, method of making and use | RESOURCE DEVELOPMENT L.L.C. (US) | 2014-05-27 | — | — | US | claimed |
| EP-2566874-A2 | SOLVENT-FREE ORGANOSILANE QUATERNARY AMMONIUM COMPOSITIONS, METHOD OF MAKING AND USE | Resource Development L.L.C. (US) | 2013-03-13 | — | — | EP | claimed |
| US-20120125226-A1 | Solvent-Free Organosilane Quaternary Ammonium Compositions, Method of Making and Use | RESOURCE DEVELOPMENT L.L.C. (US) | 2012-05-24 | — | — | US | claimed |
| WO-2011140451-A2 | SOLVENT-FREE ORGANOSILANE QUATERNARY AMMONIUM COMPOSITIONS, METHOD OF MAKING AND USE | RESOURCE DEVELOPMENT L.L.C. (US) | 2011-11-10 | — | — | WO | claimed |
| US-20110271873-A1 | Solvent-Free Organosilane Quaternary Ammonium Compositions, Method of Making and Use | Resource Development, LLC (US) | 2011-11-10 | — | — | US | claimed |
| EP-0839529-A2 | Compositions containing aliphatic monocarboxylic acid esters or amides for the treatment of skin diseases | CELLEGY PHARMACEUTICALS, INC. (US) | 1998-05-06 | — | — | EP | claimed |
| JP-2513877-B2 | — | — | 1996-07-03 | — | — | JP | claimed |
| US-5231087-A | Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids | CELLEGY PHARMACEUTICALS, INC. (US) | 1993-07-27 | — | — | US | claimed |
| EP-0515517-A4 | TREATMENT OF PRURITIS WITH ESTERS AND AMIDES | — | 1993-05-19 | — | — | EP | claimed |
| EP-0462964-A4 | TREATMENT OF SKIN DISEASES AND TUMORS | — | 1993-02-10 | — | — | EP | claimed |
| EP-0515517-A1 | TREATMENT OF PRURITIS WITH ESTERS AND AMIDES | DERMATOLOGIC RESEARCH CORPORATION (US) | 1992-12-02 | — | — | EP | claimed |
| EP-0462964-A1 | TREATMENT OF SKIN DISEASES AND TUMORS | CELLEGY PHARMACEUTICALS, INC. (US) | 1992-01-02 | — | — | EP | claimed |
| US-5057500-A | TREATMENT OF PRURITIS WITH ESTERS AND AMIDES | DERMATOLOGIC RESEARCH CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
| WO-1991012010-A1 | TREATMENT OF PRURITIS WITH ESTERS AND AMIDES | DERMATOLOGIC RESEARCH CORPORATION (US) | 1991-08-22 | — | — | WO | claimed |
| WO-1990010441-A1 | TREATMENT OF SKIN DISEASES AND TUMORS | THORNFELDT CARL R (US) | 1990-09-20 | — | — | WO | claimed |
| EP-2566874-B1 | SOLVENT-FREE ORGANOSILANE QUATERNARY AMMONIUM COMPOSITIONS, METHOD OF MAKING AND USE | RESOURCE DEV LLC (US) | 2023-01-18 | — | — | EP | disclosed |
| US-8735618-B2 | Solvent-free organosilane quaternary ammonium compositions, method of making and use | RESOURCE DEVELOPMENT L.L.C. (US) | 2014-05-27 | — | — | US | disclosed |
| US-5057500-A | TREATMENT OF PRURITIS WITH ESTERS AND AMIDES | DERMATOLOGIC RESEARCH CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| WO-1990010441-A1 | TREATMENT OF SKIN DISEASES AND TUMORS | THORNFELDT CARL R (US) | 1990-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120125226-A1 | Solvent-Free Organosilane Quaternary Ammonium Compositions, Method of Making and Use | VDAC1, CUTA, HVCN1 | DNM1 876/4885FAAH 1272/4885TRPV1 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.